MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ArQule Company Profile (NASDAQ:ARQL)

Consensus Ratings for ArQule (NASDAQ:ARQL) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.75 (102.70% upside)

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
DateFirmActionRatingPrice TargetActions
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/27/2015Royal Bank Of CanadaUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for ArQule (NASDAQ:ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214($0.12)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2012($0.09)$0.07ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for ArQule (NASDAQ:ARQL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.09)($0.09)($0.09)
Q4 20161($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)
Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ArQule (NASDAQ:ARQL)
DateHeadline
07/01/16 07:48 PMArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity
07/01/16 02:34 PMArQule, Inc. (NASDAQ:ARQL) Expected to Reach Highs Of $5 - Investor Newswire
07/01/16 02:34 PMHere's What The ArQule, Inc. (ARQL) Data Really Means - Insider Monkey (blog)
07/01/16 11:55 AMHere’s What The ArQule, Inc. (ARQL) Data Really Means -
07/01/16 10:37 AMHere’s What The ArQule, Inc. (NASDAQ:ARQL) Data Really Means
06/30/16 02:45 PMArQule (ARQL) Announces Prelim. Data on ARQ 087 Phase 1/2; Anticancer Activity Observed - StreetInsider.com
06/30/16 02:45 PMUpdate on Stock Volatility for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily
06/30/16 02:45 PMCheck on Unusual Volume for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily
06/30/16 10:27 AMArQule Presents Anti-Cancer Activity For Its ARQ 087 In Rare Liver Cancer
06/30/16 08:40 AMArQule's ARQ 087 shows evidence of anticancer activity in Phase 1/2 study in rare bile duct cancer; shares up 10% premarket -
06/26/16 02:30 PMArQule, Inc. (ARQL) Broker Price Targets For The Coming Week - Fiscal Standard
06/25/16 07:54 AMStrong Sell Calls Recommendations For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire
06/23/16 10:23 AMArQule To Present Data From Phase1/2 Trial Of ARQ 087
06/20/16 01:02 PMETF’s with exposure to ArQule, Inc. : June 20, 2016 -
06/20/16 04:00 AMArQule: Advancing a Deep and Diverse Clinical Stage Pipeline - [Accesswire] - NEW YORK, NY / ACCESSWIRE / June 20, 2016 / Rising Tide Equity Research, LLC announced today the release of its Initial Equity Report on ArQule, Inc (NASDAQ: ARQL), a biopharmaceutical company engaged ...
06/19/16 07:18 AMThis Weeks Broker Views For ArQule, Inc. (ARQL) - Fiscal Standard
06/17/16 02:32 PMStrong Buy Calls Count For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire
06/15/16 07:23 AMRecently Issued Stock Ratings For ArQule, Inc. (ARQL) - Fiscal Standard
06/08/16 10:24 AMValeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss -
06/01/16 08:41 PMInsiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL) - HNN - Insiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL)HNNAccording to the latest SEC filings, insiders at ArQule Inc. (NASDAQ:ARQL) have increased their position in the stock by 2.33% over the past 6 months. Insiders now own 1.10% of total outstanding shares. There are both legal and illegal types of insider ...and more »
05/26/16 07:09 PMArQule, Inc. (ARQL) Updated Broker Price Targets - Share Trading News - ArQule, Inc. (ARQL) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of ArQule, Inc. (ARQL). The latest reports which are currently in issue on Thursday 26th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...
05/26/16 11:12 AMARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/26/16 12:08 AMInsiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL) - Wall Street Hints and News - Insiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at ArQule Inc. (NASDAQ:ARQL) have increased their position in the stock by 2.24% over the past 6 months. Insiders now own 1.10% of total outstanding shares. There are both legal and illegal types of insider ...and more »
05/24/16 12:07 AMArQule, Inc. (NASDAQ:ARQL) Impact Score At 100 - Stocks Daily - ArQule, Inc. (NASDAQ:ARQL) Impact Score At 100Stocks DailyAlpha One explored various online articles released on ArQule, Inc. (NASDAQ:ARQL), and it set a daily sentiment score of 0.56 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued ...and more »
05/17/16 12:56 PMArQule, Inc. :ARQL-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/08/16 08:45 PMArQule, Inc. (ARQL) Broker Price Targets For The Coming Week - Share Trading News - ArQule, Inc. (ARQL) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of ArQule, Inc. (ARQL). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...
05/06/16 07:19 PMArQule, Inc. (NASDAQ:ARQL) ABR Of 2.5 - RealistInvestor.com - ArQule, Inc. (NASDAQ:ARQL) ABR Of 2.5RealistInvestor.comThere are numerous brokerages operating in the market, and each one of them uses a different process to prepare the research reports on a stock. As a result, investors have to study more than one research report before taking an investment call on a stock.and more »
05/05/16 12:27 AMEARNINGS SUMMARY: Details of ArQule Inc. Q1 Earnings Report - Below are the earnings highlights for ArQule Inc. (ARQL): -Earnings: -$4.98 million in Q1 vs. -$4.55 million in the same period last year. -EPS: -$0.08 in Q1 vs. -$0.07 in the same period last year. -Analysts projected -$0.07 per share -Revenue ...
05/04/16 05:40 PMEdited Transcript of ARQL earnings conference call or presentation 4-May-16 1:00pm GMT -
05/04/16 07:01 AMARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/04/16 06:20 AMArQule reports 1Q loss -
05/04/16 06:07 AMQ1 2016 ArQule Inc Earnings Release - Before Market Open -
05/04/16 06:03 AM7:03 am ArQule reports EPS in-line, beats on revs; guides FY16 EPS in-line, revs in-line -
05/04/16 06:00 AMArQule Reports First Quarter 2016 Financial Results - [GlobeNewswire] - Conference call scheduled today at 9:00 a.m. ET. BURLINGTON, Mass., May 04, 2016-- ArQule, Inc. today announced its financial results for the first quarter of 2016.. For the quarter ended March 31, 2016, ...
05/02/16 08:45 PMArQule, Inc. (NASDAQ:ARQL) Boasts An Average Rating Of 4 - Stocks Daily - ArQule, Inc. (NASDAQ:ARQL) Boasts An Average Rating Of 4Stocks DailyAlpha One applies algorithm-based analytics for assessing a stock sentiment as per the published released on web channels. In this evaluation process, the group accesses the most relevant news platforms on a daily basis. ArQule, Inc. (NASDAQ:ARQL) has ...and more »
05/02/16 02:18 AMLatest Analyst Ratings For ArQule, Inc. (ARQL) - Share Trading News - Latest Analyst Ratings For ArQule, Inc. (ARQL)Share Trading NewsArQule, Inc. has a 50 day moving average of 1.61 and a 200 day moving average of 1.95. The stock's market capitalization is 102.51M, it has a 52-week low of 1.37 and a 52-week high of 2.65. The share price of the company (ARQL) was down -1.21%, with a ...
04/28/16 08:45 PMBroker Outlook For ArQule, Inc. (ARQL) - Share Trading News - Broker Outlook For ArQule, Inc. (ARQL)Share Trading NewsIts lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (c-MET or MET) and its biological pathway. The Company's product candidates include ARQ 092, ARQ 087, ARQ 751 and ...
04/26/16 07:17 PMHow Many ArQule, Inc. (NASDAQ:ARQL)'s Analysts Are Bullish? - CCH Daily News - How Many ArQule, Inc. (NASDAQ:ARQL)'s Analysts Are Bullish?CCH Daily NewsOut of 3 analysts covering ArQule (NASDAQ:ARQL), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. ArQule has been the topic of 2 analyst reports since December 9, 2015 according to StockzIntelligence Inc. Below is a list of ...
04/26/16 07:17 PMCompany in Focus - ArQule, Inc. (NASDAQ:ARQL) - The Post - Company in Focus - ArQule, Inc. (NASDAQ:ARQL)The PostShares of ArQule, Inc. (NASDAQ:ARQL) have been provided with a top rating from Beta Systems research. This rating takes into consideration analyst opinions, fundamentals and potential future earnings growth. The compiled data also uses EPS and target ...
04/22/16 08:52 PMArQule, Inc. (ARQL) - Broker Update - Risers & Fallers - ArQule, Inc. (ARQL) - Broker UpdateRisers & FallersIts lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (c-MET or MET) and its biological pathway. The Company's product candidates include ARQ 092, ARQ 087, ARQ 751 and ...
04/21/16 08:50 PMBiotech Gainers: ArQule Inc. (NASDAQ:ARQL), OncoSec Medical (NASDAQ:ONCS), Kite Pharma, Inc. (NASDAQ:KITE ... - KC Register - Biotech Gainers: ArQule Inc. (NASDAQ:ARQL), OncoSec Medical (NASDAQ:ONCS), Kite Pharma, Inc. (NASDAQ:KITE ...KC RegisterArQule Inc. (NASDAQ:ARQL) announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May 4, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these ...and more »
04/20/16 06:30 AMArQule To Report First Quarter 2016 Financial Results On May 4, 2016 - [GlobeNewswire] - BURLINGTON, Mass., April 20, 2016-- ArQule, Inc. today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May 4, 2016. The Company will hold a conference ...
04/14/16 03:32 PMARQULE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
04/12/16 08:41 PMShares in Focus - ArQule, Inc. (NASDAQ:ARQL) - Stock Caller - Shares in Focus - ArQule, Inc. (NASDAQ:ARQL)Stock CallerArQule, Inc. (NASDAQ:ARQL) shares have been given a top rating from Beta Systems research. This rating considers fundamentals, potential future earnings growth and analyst opinions. This data also uses analyst target price and EPS predictions. Traders ...and more »
04/12/16 01:12 AMArqule Incorporated (NASDAQ:ARQL) Shorted Shares Increased By 1.39% - RiversideGazette.com - Arqule Incorporated (NASDAQ:ARQL) Shorted Shares Increased By 1.39%RiversideGazette.comThe short interest to Arqule Incorporated's float is 2.27%. The stock is up 2.61% or $0.04 after the news, hitting $1.57 per share. About 41,575 shares traded hands. ArQule, Inc. (NASDAQ:ARQL) has declined 8.93% since September 2, 2015 and is ...and more »
04/09/16 02:39 AMArQule, Inc. (ARQL) Updated Analyst Coverage - Risers & Fallers - ArQule, Inc. (ARQL) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of ArQule, Inc. (ARQL). According to the latest broker reports outstanding on Friday 8th of April, 0 analysts have a rating of “strong buy”, 2 analysts “buy”, 2 analysts ...
04/05/16 08:04 PMStock Focus on - ArQule, Inc. (NASDAQ:ARQL) - Stock Caller - Stock Focus on - ArQule, Inc. (NASDAQ:ARQL)Stock CallerShares of ArQule, Inc. (NASDAQ:ARQL) have received a top rating according to Beta Systems research. The rating takes into consideration fundamentals, analyst views, and potential future earnings growth. The compiled data also includes analyst target ...and more »
04/05/16 06:30 AMArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016 - [GlobeNewswire] - BURLINGTON, Mass., April 05, 2016-- ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present ...
03/30/16 07:12 PMKeryx Up on Positive Auryxia Data in Iron Deficiency Anemia - Some better-ranked stocks in the health care sector are Actelion Ltd (ALIOF - Snapshot Report), Sucampo Pharmaceuticals (SCMP - Analyst Report) and ArQule, Inc. (ARQL - Snapshot Report). All the three stocks sport a Zacks Rank #1 (Strong Buy).
03/29/16 07:06 PMStock to Watch - ArQule, Inc. (NASDAQ:ARQL) - Stock Caller - Stock to Watch - ArQule, Inc. (NASDAQ:ARQL)Stock CallerArQule, Inc. (NASDAQ:ARQL) shares have been given a top rating based on research from Beta Systems. The rating factors in potential future earnings growth, analyst opinions, and fundamentals. The compiled data also includes target price and earnings ...and more »
About ArQule

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARQL
  • CUSIP: 04269E10
Key Metrics:
  • Previous Close: $1.85
  • 50 Day Moving Average: $1.76
  • 200 Day Moving Average: $1.76
  • P/E Ratio: N/A
  • P/E Growth: -1.12
  • Market Cap: $131.46M
  • Current Quarter EPS Consensus Estimate: $-0.34 EPS
Additional Links:
ArQule (NASDAQ:ARQL) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha